بیماری مزمن انسداد ریه و فعالیت ورزشی: با نگاه اجمالی به نقش سیستم ایمنی ذاتی در بیماری زایی و تاثیر تمرینات ورزشی بر آن ها(مطالعه روایی)
Nafas Journal,
Vol. 10 No. 2 (1402),
20 July 2023
Abstract
زمینه و هدف: ایمنی ذاتی نقش مهمی را در بیماری مزمن انسداد ریه که به عنوان یک بیماری التهابی پیشرونده شناخته شده است، ایفا می کند. به دلیل گسترش این بیماری بیش از گذشته ضرورت پرداختن به فعالیت های ورزشی در بیماران مبتلا به انسداد مزمن ریه با توجه به اثرات ایمونولوژیک و فیزیولوژیک آن بر بهبود این بیماران مطرح شده است. در این مطالعه ضمن بررسی اثرات ایمنی ذاتی بر بیماری ذایی و تاثیر تمرینات ورزشی مختلف بر ایمنی ذاتی بیماران مبتلا به انسداد مزمن ریه، نسخه ورزشی مناسب برای انجام فعالیت ورزشی در دوران ابتلا به این بیماری ارائه شده است.
مواد و روش ها: در این مطالعه مروری مقالات مرتطب از تمام پایگاه های اطلاعاتی شامل اسکوپوس، پابمد، گوگل اسکالر، سامانه همایش های معتبر علمی، مگیران و نورد مورد بررسی قرار گرفت. همچنین در فرآیند جست و جو از کلید واژه های بیماری انسداد مزمن ریه، ایمنی ذاتی و بیماری مزمن انسداد ریه، تمرینات ورزشی و بیماری انسداد مزمن ریه استفاده شد.
ملاحظات اخلاقی: اصول اخلاقی در نگارش مقاله، طبق دستورالعمل کمیته ملی اخلاق و آیین نامه COPE رعایت شده است.
یافته ها: فعالیت های ورزشی مختلف از جمله تمرینات ترکیبی(هوازی، مقاومتی و تنفسی) با توجه با اثرات فیزیولوژیکی خود می توانند برای افزایش عملکرد ایمنی ذاتی در افراد مبتلا به بیماری مزمن انسداد ریه مفید باشند و به عنوان یک مکمل درمانی در کاهش و بهبود علائم بالینی و کاهش تنگی نفس و همچنین افزایش کیفیت زندگی در این بیماران مورد استفاده قرار گیرند.
نتیجه گیری: با توجه به گسترش بیماری انسداد مزمن ریه در جهان، پیشنهاد می شود از فعالیت های ورزشی با شدت و مدت مناسب برای کمک به بهبود بیماران استفاده شود.
- : بیماری مزمن انسداد ریه، ایمنی ذاتی، تمرینات ورزشی، تمرینات مقاومتی، تمرینات هوازی
How to Cite
References
2- Çolak Y, Afzal S, Nordestgaard BG, Vestbo J, Lange P. Prevalence, Characteristics, and Prognosis of Early Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. Am J Respir Crit Care Med. 2020 Mar 15;201(6):671-680. doi: 10.1164/rccm.201908-1644OC. PMID: 31770495; PMCID: PMC7068820.
3. Hashemi SY, Momenabadi V, Faramarzi A, Kiani A. Trends in burden of chronic obstructive pulmonary disease in Iran, 1995-2015: findings from the global burden of disease study. Arch Public Health. 2020 May 25;78:45. doi: 10.1186/s13690-020-00426-x. PMID: 32509302; PMCID: PMC7249692.
4. Laniado-Laborín R. Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21 century. Int J Environ Res Public Health. 2009 Jan;6(1):209-24. doi: 10.3390/ijerph6010209. Epub 2009 Jan 9. PMID: 19440278; PMCID: PMC2672326.
5. Tkacova R. Systemic inflammation in chronic obstructive pulmonary disease: may adipose tissue play a role? Review of the literature and future perspectives. Mediators Inflamm. 2010;2010:585989. doi: 10.1155/2010/585989. Epub 2010 Apr 20. PMID: 20414465; PMCID: PMC2857618.
6. Agustí AG. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(4):367-70; discussion 371-2. doi: 10.1513/pats.200504-026SR. PMID: 16267364.
7. Johns DP, Walters JA, Walters EH. Diagnosis and early detection of COPD using spirometry. J Thorac Dis. 2014 Nov;6(11):1557-69. doi: 10.3978/j.issn.2072-1439.2014.08.18. PMID: 25478197; PMCID: PMC4255165.
8. Ruppel GL, Carlin BW, Hart M, Doherty DE. Office Spirometry in Primary Care for the Diagnosis and Management of COPD: National Lung Health Education Program Update. Respir Care. 2018 Feb;63(2):242-252. doi: 10.4187/respcare.05710. PMID: 29367384.
9. Kotlyarov, S.N. Spirometry screening in evaluation of chronic obstructive pulmonary disease at primary care. I.P. Pavlov. Russ. Med. Biol. Her. 2011, 19, 91–95.
10. Sethi S, Maloney J, Grove L, Wrona C, Berenson CS. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006 May 1;173(9):991-8. doi: 10.1164/rccm.200509-1525OC. Epub 2006 Feb 10. PMID: 16474030; PMCID: PMC2662918.
11. Hogea SP, Tudorache E, Fildan AP, Fira-Mladinescu O, Marc M, Oancea C. Risk factors of chronic obstructive pulmonary disease exacerbations. Clin Respir J. 2020 Mar;14(3):183-197. doi: 10.1111/crj.13129. Epub 2020 Jan 21. PMID: 31814260.
12. Wilkinson TM, Patel IS, Wilks M, Donaldson GC, Wedzicha JA. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003 Apr 15;167(8):1090-5. doi: 10.1164/rccm.200210-1179OC. Epub 2003 Jan 24. PMID: 12684248.
13. Viniol C, Vogelmeier CF. Exacerbations of COPD. Eur Respir Rev. 2018 Mar 14;27(147):170103. doi: 10.1183/16000617.0103-2017. PMID: 29540496; PMCID: PMC9488662.
15. Galizia G, Cacciatore F, Testa G, Della-Morte D, Mazzella F, Langellotto A, Raucci C, Gargiulo G, Ferrara N, Rengo F, Abete P. Role of clinical frailty on long-term mortality of elderly subjects with and without chronic obstructive pulmonary disease. Aging Clin Exp Res. 2011 Apr;23(2):118-25. doi: 10.1007/BF03351076. PMID: 21743290.
16. Vaz Fragoso CA, Enright PL, McAvay G, Van Ness PH, Gill TM. Frailty and respiratory impairment in older persons. Am J Med. 2012 Jan;125(1):79-86. doi: 10.1016/j.amjmed.2011.06.024. PMID: 22195532; PMCID: PMC3246194.
17. Bernabeu-Mora R, García-Guillamón G, Valera-Novella E, Giménez-Giménez LM, Escolar-Reina P, Medina-Mirapeix F. Frailty is a predictive factor of readmission within 90 days of hospitalization for acute exacerbations of chronic obstructive pulmonary disease: a longitudinal study. Ther Adv Respir Dis. 2017 Oct;11(10):383-392. doi: 10.1177/1753465817726314. Epub 2017 Aug 29. PMID: 28849736; PMCID: PMC5933665.
18. Kon SS, Jones SE, Schofield SJ, Banya W, Dickson MJ, Canavan JL, Nolan CM, Haselden BM, Polkey MI, Cullinan P, Man WD. Gait speed and readmission following hospitalisation for acute exacerbations of COPD: a prospective study. Thorax. 2015 Dec;70(12):1131-7. doi: 10.1136/thoraxjnl-2015-207046. Epub 2015 Aug 17. PMID: 26283709.
19. . Kusunose M, Oga T, Nakamura S, Hasegawa Y, Nishimura K. Frailty and patient-reported outcomes in subjects with chronic obstructive pulmonary disease: are they independent entities? BMJ Open Respir Res. 2017;4(1):e000196. doi:10.1136/bmjresp-2017-000196
20. Brawley LR, Rejeski WJ, King AC. Promoting physical activity for older adults: the challenges for changing behavior. Am J Prev Med. 2003 Oct;25(3 Suppl 2):172-83. doi: 10.1016/s0749-3797(03)00182-x. PMID: 14552942.
21. Jadczak AD, Dollard J, Mahajan N, Visvanathan R. The perspectives of pre-frail and frail older people on being advised about exercise: a qualitative study. Fam Pract. 2018 May 23;35(3):330-335. doi: 10.1093/fampra/cmx108. PMID: 29145588.
22. van Dam van Isselt EF, van Eijk M, van Geloven N, Groenewegen-Sipkema KH, van den Berg JK, Nieuwenhuys CMA, Chavannes NH, Achterberg WP. A Prospective Cohort Study on the Effects of Geriatric Rehabilitation Following Acute Exacerbations of COPD. J Am Med Dir Assoc. 2019 Jul;20(7):850-856.e2. doi: 10.1016/j.jamda.2019.02.025. Epub 2019 Apr 11. PMID: 30982715.
23. Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th edition. New York: Garland Science; 2002. Innate Immunity. Available from: https://www.ncbi.nlm.nih.gov/books/NBK26846/
24. Kotlyarov S, Kotlyarova A. Molecular Mechanisms of Lipid Metabolism Disorders in Infectious Exacerbations of Chronic Obstructive Pulmonary Disease. Int J Mol Sci. 2021 Jul 17;22(14):7634. doi: 10.3390/ijms22147634. PMID: 34299266; PMCID: PMC8308003.
25. Töpfer E, Boraschi D, Italiani P. Innate Immune Memory: The Latest Frontier of Adjuvanticity. J Immunol Res. 2015;2015:478408. doi: 10.1155/2015/478408. Epub 2015 Aug 25. PMID: 26380322; PMCID: PMC4561982.
26. Valavanidis A, Vlachogianni T, Fiotakis K. Tobacco smoke: involvement of reactive oxygen species and stable free radicals in mechanisms of oxidative damage, carcinogenesis and synergistic effects with other respirable particles. Int J Environ Res Public Health. 2009 Feb;6(2):445-62. doi: 10.3390/ijerph6020445. Epub 2009 Feb 2. PMID: 19440393; PMCID: PMC2672368.
27. Bals R, Hiemstra PS. Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Respir J. 2004 Feb;23(2):327-33. doi: 10.1183/09031936.03.00098803. PMID: 14979512.
28. Parker D, Prince A. Innate immunity in the respiratory epithelium. Am J Respir Cell Mol Biol. 2011 Aug;45(2):189-201. doi: 10.1165/rcmb.2011-0011RT. Epub 2011 Feb 17. PMID: 21330463; PMCID: PMC3175551.
29. Johnston SL, Goldblatt DL, Evans SE, Tuvim MJ, Dickey BF. Airway Epithelial Innate Immunity. Front Physiol. 2021 Nov 26;12:749077. doi: 10.3389/fphys.2021.749077. PMID: 34899381; PMCID: PMC8662554.
30. Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest. 2002 Mar;109(5):571-7. doi: 10.1172/JCI15217. PMID: 11877463; PMCID: PMC150901.
31. Hariri BM, Cohen NA. New insights into upper airway innate immunity. Am J Rhinol Allergy. 2016 Sep;30(5):319-23. doi: 10.2500/ajra.2016.30.4360. PMID: 27657896; PMCID: PMC5013235.
32. Fahy JV, Dickey BF. Airway mucus function and dysfunction. N Engl J Med. 2010 Dec 2;363(23):2233-47. doi: 10.1056/NEJMra0910061. PMID: 21121836; PMCID: PMC4048736.
33. Hiemstra PS. Antimicrobial peptides in the real world: implications for cystic fibrosis. Eur Respir J. 2007 Apr;29(4):617-8. doi: 10.1183/09031936.00017007. PMID: 17400874.
34. Li J, Ye Z. The Potential Role and Regulatory Mechanisms of MUC5AC in Chronic Obstructive Pulmonary Disease. Molecules. 2020 Sep 27;25(19):4437. doi: 10.3390/molecules25194437. PMID: 32992527; PMCID: PMC7582261.
35. Saco TV, Breitzig MT, Lockey RF, Kolliputi N. Epigenetics of Mucus Hypersecretion in Chronic Respiratory Diseases. Am J Respir Cell Mol Biol. 2018 Mar;58(3):299-309. doi: 10.1165/rcmb.2017-0072TR. PMID: 29096066; PMCID: PMC5854956.
36. Radicioni G, Ceppe A, Ford AA, Alexis NE, Barr RG, Bleecker ER, Christenson SA, Cooper CB, Han MK, Hansel NN, Hastie AT, Hoffman EA, Kanner RE, Martinez FJ, Ozkan E, Paine R 3rd, Woodruff PG, O'Neal WK, Boucher RC, Kesimer M. Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2021 Nov;9(11):1241-1254. doi: 10.1016/S2213-2600(21)00079-5. Epub 2021 May 28. PMID: 34058148; PMCID: PMC8570975.
37. Leopold PL, O'Mahony MJ, Lian XJ, Tilley AE, Harvey BG, Crystal RG. Smoking is associated with shortened airway cilia. PLoS One. 2009 Dec 16;4(12):e8157. doi: 10.1371/journal.pone.0008157. PMID: 20016779; PMCID: PMC2790614.
38. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. 2003 Sep;3(9):710-20. doi: 10.1038/nri1180. PMID: 12949495.
39. Herr C, Beisswenger C, Hess C, Kandler K, Suttorp N, Welte T, Schroeder JM, Vogelmeier C; R Bals for the CAPNETZ Study Group. Suppression of pulmonary innate host defence in smokers. Thorax. 2009 Feb;64(2):144-9. doi: 10.1136/thx.2008.102681. Epub 2008 Oct 13. PMID: 18852155.
40. Feng Z, Jiang B, Chandra J, Ghannoum M, Nelson S, Weinberg A. Human beta-defensins: differential activity against candidal species and regulation by Candida albicans. J Dent Res. 2005 May;84(5):445-50. doi: 10.1177/154405910508400509. PMID: 15840781.
41. Wilson SS, Wiens ME, Smith JG. Antiviral mechanisms of human defensins. J Mol Biol. 2013 Dec 13;425(24):4965-80. doi: 10.1016/j.jmb.2013.09.038. Epub 2013 Oct 2. PMID: 24095897; PMCID: PMC3842434.
42. Proud D, Sanders SP, Wiehler S. Human rhinovirus infection induces airway epithelial cell production of human beta-defensin 2 both in vitro and in vivo. J Immunol. 2004 Apr 1;172(7):4637-45. doi: 10.4049/jimmunol.172.7.4637. PMID: 15034083.
43. Harder J, Meyer-Hoffert U, Teran LM, Schwichtenberg L, Bartels J, Maune S, Schröder JM. Mucoid Pseudomonas aeruginosa, TNF-alpha, and IL-1beta, but not IL-6, induce human beta-defensin-2 in respiratory epithelia. Am J Respir Cell Mol Biol. 2000 Jun;22(6):714-21. doi: 10.1165/ajrcmb.22.6.4023. PMID: 10837369.
44. Jiang YY, Xiao W, Zhu MX, Yang ZH, Pan XJ, Zhang Y, Sun CC, Xing Y. The effect of human antibacterial peptide LL-37 in the pathogenesis of chronic obstructive pulmonary disease. Respir Med. 2012 Dec;106(12):1680-9. doi: 10.1016/j.rmed.2012.08.018. Epub 2012 Sep 14. PMID: 22981321.
45. De Smet K, Contreras R. Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol Lett. 2005 Sep;27(18):1337-47. doi: 10.1007/s10529-005-0936-5. PMID: 16215847.
46. Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock RE. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol. 2002 Oct 1;169(7):3883-91. doi: 10.4049/jimmunol.169.7.3883. PMID: 12244186.
47. Jiang W, Sunkara LT, Zeng X, Deng Z, Myers SM, Zhang G. Differential regulation of human cathelicidin LL-37 by free fatty acids and their analogs. Peptides. 2013 Dec;50:129-38. doi: 10.1016/j.peptides.2013.10.008. Epub 2013 Oct 18. PMID: 24140860.
48. Markovič T, Jakopin Ž, Dolenc MS, Mlinarič-Raščan I. Structural features of subtype-selective EP receptor modulators. Drug Discov Today. 2017 Jan;22(1):57-71. doi: 10.1016/j.drudis.2016.08.003. Epub 2016 Aug 6. PMID: 27506873.
49. Sastre B, del Pozo V. Role of PGE2 in asthma and nonasthmatic eosinophilic bronchitis. Mediators Inflamm. 2012;2012:645383. doi: 10.1155/2012/645383. Epub 2012 Mar 19. PMID: 22529528; PMCID: PMC3316983.
50. Vancheri C, Mastruzzo C, Sortino MA, Crimi N. The lung as a privileged site for the beneficial actions of PGE2. Trends Immunol. 2004 Jan;25(1):40-6. doi: 10.1016/j.it.2003.11.001. PMID: 14698283.
51. Bayarri MA, Milara J, Estornut C, Cortijo J. Nitric Oxide System and Bronchial Epithelium: More Than a Barrier. Front Physiol. 2021 Jun 30;12:687381. doi: 10.3389/fphys.2021.687381. PMID: 34276407; PMCID: PMC8279772.
52. Wink DA, Hines HB, Cheng RY, Switzer CH, Flores-Santana W, Vitek MP, Ridnour LA, Colton CA. Nitric oxide and redox mechanisms in the immune response. J Leukoc Biol. 2011 Jun;89(6):873-91. doi: 10.1189/jlb.1010550. Epub 2011 Jan 13. PMID: 21233414; PMCID: PMC3100761.
53. Jiang WT, Liu XS, Xu YJ, Ni W, Chen SX. Expression of Nitric Oxide Synthase Isoenzyme in Lung Tissue of Smokers with and without Chronic Obstructive Pulmonary Disease. Chin Med J (Engl). 2015 Jun 20;128(12):1584-9. doi: 10.4103/0366-6999.158309. PMID: 26063358; PMCID: PMC4733731.
54. Hellermann GR, Nagy SB, Kong X, Lockey RF, Mohapatra SS. Mechanism of cigarette smoke condensate-induced acute inflammatory response in human bronchial epithelial cells. Respir Res. 2002;3(1):22. doi: 10.1186/rr172. Epub 2002 Jul 10. PMID: 12204101; PMCID: PMC150508.
55. Ma WJ, Sun YH, Jiang JX, Dong XW, Zhou JY, Xie QM. Epoxyeicosatrienoic acids attenuate cigarette smoke extract-induced interleukin-8 production in bronchial epithelial cells. Prostaglandins Leukot Essent Fatty Acids. 2015 Mar;94:13-9. doi: 10.1016/j.plefa.2014.10.006. Epub 2014 Nov 4. PMID: 25467970.
56. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197-216. doi: 10.1146/annurev.immunol.20.083001.084359. Epub 2001 Oct 4. PMID: 11861602.
57. MacRedmond RE, Greene CM, Dorscheid DR, McElvaney NG, O'Neill SJ. Epithelial expression of TLR4 is modulated in COPD and by steroids, salmeterol and cigarette smoke. Respir Res. 2007 Nov 22;8(1):84. doi: 10.1186/1465-9921-8-84. PMID: 18034897; PMCID: PMC2194695.
58. Lee SW, Kim DR, Kim TJ, Paik JH, Chung JH, Jheon S, Huh JW, Lee JH, Lee CT. The association of down-regulated toll-like receptor 4 expression with airflow limitation and emphysema in smokers. Respir Res. 2012 Nov 21;13(1):106. doi: 10.1186/1465-9921-13-106. PMID: 23170858; PMCID: PMC3546871.
59. Di Stefano A, Ricciardolo FLM, Caramori G, Adcock IM, Chung KF, Barnes PJ, Brun P, Leonardi A, Andò F, Vallese D, Gnemmi I, Righi L, Cappello F, Balbi B. Bronchial inflammation and bacterial load in stable COPD is associated with TLR4 overexpression. Eur Respir J. 2017 May 23;49(5):1602006. doi: 10.1183/13993003.02006-2016. PMID: 28536249.
60. Sand JMB, Rønnow SR, Langholm LL, Karsdal MA, Manon-Jensen T, Tal-Singer R, Miller BE, Vestbo J, Leeming DJ. Combining biomarkers of clot resolution and alveolar basement membrane destruction predicts mortality in the ECLIPSE COPD cohort. Respir Med. 2020 Nov;173:106185. doi: 10.1016/j.rmed.2020.106185. Epub 2020 Oct 2. PMID: 33035747; PMCID: PMC7530580.
61. Kieliszek M, Lipinski B. Pathophysiological significance of protein hydrophobic interactions: An emerging hypothesis. Med Hypotheses. 2018 Jan;110:15-22. doi: 10.1016/j.mehy.2017.10.021. Epub 2017 Dec 22. PMID: 29317059.
62. Vlahos R, Bozinovski S. Role of alveolar macrophages in chronic obstructive pulmonary disease. Front Immunol. 2014 Sep 10;5:435. doi: 10.3389/fimmu.2014.00435. PMID: 25309536; PMCID: PMC4160089.
63. Kapellos TS, Bassler K, Aschenbrenner AC, Fujii W, Schultze JL. Dysregulated Functions of Lung Macrophage Populations in COPD. J Immunol Res. 2018 Feb 18;2018:2349045. doi: 10.1155/2018/2349045. PMID: 29670919; PMCID: PMC5835245.
64. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000 Jun 15;164(12):6166-73. doi: 10.4049/jimmunol.164.12.6166. PMID: 10843666.
65. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004 Dec;25(12):677-86. doi: 10.1016/j.it.2004.09.015. PMID: 15530839.
66. Orecchioni M, Ghosheh Y, Pramod AB, Ley K. Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS-) vs. Alternatively Activated Macrophages. Front Immunol. 2019 May 24;10:1084. doi: 10.3389/fimmu.2019.01084. Erratum in: Front Immunol. 2020 Feb 25;11:234. PMID: 31178859; PMCID: PMC6543837.
67. Saqib U, Sarkar S, Suk K, Mohammad O, Baig MS, Savai R. Phytochemicals as modulators of M1-M2 macrophages in inflammation. Oncotarget. 2018 Apr 3;9(25):17937-17950. doi: 10.18632/oncotarget.24788. PMID: 29707159; PMCID: PMC5915167.
68. Wang N, Liang H, Zen K. Molecular mechanisms that influence the macrophage m1-m2 polarization balance. Front Immunol. 2014 Nov 28;5:614. doi: 10.3389/fimmu.2014.00614. PMID: 25506346; PMCID: PMC4246889.
69. Viola A, Munari F, Sánchez-Rodríguez R, Scolaro T, Castegna A. The Metabolic Signature of Macrophage Responses. Front Immunol. 2019 Jul 3;10:1462. doi: 10.3389/fimmu.2019.01462. PMID: 31333642; PMCID: PMC6618143.
70. Brown BN, Valentin JE, Stewart-Akers AM, McCabe GP, Badylak SF. Macrophage phenotype and remodeling outcomes in response to biologic scaffolds with and without a cellular component. Biomaterials. 2009 Mar;30(8):1482-91. doi: 10.1016/j.biomaterials.2008.11.040. Epub 2009 Jan 1. PMID: 19121538; PMCID: PMC2805023.
71. Italiani P, Boraschi D. From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation. Front Immunol. 2014 Oct 17;5:514. doi: 10.3389/fimmu.2014.00514. PMID: 25368618; PMCID: PMC4201108.
72. Hodge S, Hodge G, Ahern J, Jersmann H, Holmes M, Reynolds PN. Smoking alters alveolar macrophage recognition and phagocytic ability: implications in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2007 Dec;37(6):748-55. doi: 10.1165/rcmb.2007-0025OC. Epub 2007 Jul 13. PMID: 17630319.
73. Berenson CS, Kruzel RL, Eberhardt E, Sethi S. Phagocytic dysfunction of human alveolar macrophages and severity of chronic obstructive pulmonary disease. J Infect Dis. 2013 Dec 15;208(12):2036-45. doi: 10.1093/infdis/jit400. Epub 2013 Aug 1. PMID: 23908477; PMCID: PMC3836465.
74. Han CZ, Juncadella IJ, Kinchen JM, Buckley MW, Klibanov AL, Dryden K, Onengut-Gumuscu S, Erdbrügger U, Turner SD, Shim YM, Tung KS, Ravichandran KS. Macrophages redirect phagocytosis by non-professional phagocytes and influence inflammation. Nature. 2016 Nov 24;539(7630):570-574. doi: 10.1038/nature20141. Epub 2016 Nov 7. PMID: 27820945; PMCID: PMC5799085.
75. Grassin-Delyle S, Abrial C, Salvator H, Brollo M, Naline E, Devillier P. The Role of Toll-Like Receptors in the Production of Cytokines by Human Lung Macrophages. J Innate Immun. 2020;12(1):63-73. doi: 10.1159/000494463. Epub 2018 Dec 17. PMID: 30557876; PMCID: PMC6959095.
76. Karimi K, Sarir H, Mortaz E, Smit JJ, Hosseini H, De Kimpe SJ, Nijkamp FP, Folkerts G. Toll-like receptor-4 mediates cigarette smoke-induced cytokine production by human macrophages. Respir Res. 2006 Apr 19;7(1):66. doi: 10.1186/1465-9921-7-66. PMID: 16620395; PMCID: PMC1481582.
77. Zhang J, Xu Q, Sun W, Zhou X, Fu D, Mao L. New Insights into the Role of NLRP3 Inflammasome in Pathogenesis and Treatment of Chronic Obstructive Pulmonary Disease. J Inflamm Res. 2021 Aug 26;14:4155-4168. doi: 10.2147/JIR.S324323. PMID: 34471373; PMCID: PMC8405160.
78. Foronjy R, Nkyimbeng T, Wallace A, Thankachen J, Okada Y, Lemaitre V, D'Armiento J. Transgenic expression of matrix metalloproteinase-9 causes adult-onset emphysema in mice associated with the loss of alveolar elastin. Am J Physiol Lung Cell Mol Physiol. 2008 Jun;294(6):L1149-57. doi: 10.1152/ajplung.00481.2007. Epub 2008 Apr 11. PMID: 18408070.
79. Russell RE, Thorley A, Culpitt SV, Dodd S, Donnelly LE, Demattos C, Fitzgerald M, Barnes PJ. Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. Am J Physiol Lung Cell Mol Physiol. 2002 Oct;283(4):L867-73. doi: 10.1152/ajplung.00020.2002. PMID: 12225964.
80. Wallace AM, Sandford AJ, English JC, Burkett KM, Li H, Finley RJ, Müller NL, Coxson HO, Paré PD, Abboud RT. Matrix metalloproteinase expression by human alveolar macrophages in relation to emphysema. COPD. 2008 Feb;5(1):13-23. doi: 10.1080/15412550701817789. PMID: 18259971.
81. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016 Jul;138(1):16-27. doi: 10.1016/j.jaci.2016.05.011. Epub 2016 May 27. PMID: 27373322.
82. Jasper AE, McIver WJ, Sapey E, Walton GM. Understanding the role of neutrophils in chronic inflammatory airway disease. F1000Res. 2019 Apr 26;8:F1000 Faculty Rev-557. doi: 10.12688/f1000research.18411.1. PMID: 31069060; PMCID: PMC6489989.
83. Shaykhiev R, Crystal RG. Innate immunity and chronic obstructive pulmonary disease: a mini-review. Gerontology. 2013;59(6):481-9. doi: 10.1159/000354173. Epub 2013 Sep 3. PMID: 24008598; PMCID: PMC3833667.
84. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767-811. doi: 10.1146/annurev.immunol.18.1.767. PMID: 10837075.
85. Freeman CM, Curtis JL. Lung Dendritic Cells: Shaping Immune Responses throughout Chronic Obstructive Pulmonary Disease Progression. Am J Respir Cell Mol Biol. 2017 Feb;56(2):152-159. doi: 10.1165/rcmb.2016-0272TR. PMID: 27767327; PMCID: PMC6222925.
86. Tsoumakidou M, Koutsopoulos AV, Tzanakis N, Dambaki K, Tzortzaki E, Zakynthinos S, Jeffery PK, Siafakas NM. Decreased small airway and alveolar CD83+ dendritic cells in COPD. Chest. 2009 Sep;136(3):726-733. doi: 10.1378/chest.08-2824. Epub 2009 May 22. PMID: 19465512.
87. Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, Hill K, Holland AE, Lareau SC, Man WD, Pitta F, Sewell L, Raskin J, Bourbeau J, Crouch R, Franssen FM, Casaburi R, Vercoulen JH, Vogiatzis I, Gosselink R, Clini EM, Effing TW, Maltais F, van der Palen J, Troosters T, Janssen DJ, Collins E, Garcia-Aymerich J, Brooks D, Fahy BF, Puhan MA, Hoogendoorn M, Garrod R, Schols AM, Carlin B, Benzo R, Meek P, Morgan M, Rutten-van Mölken MP, Ries AL, Make B, Goldstein RS, Dowson CA, Brozek JL, Donner CF, Wouters EF; ATS/ERS Task Force on Pulmonary Rehabilitation. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013 Oct 15;188(8):e13-64. doi: 10.1164/rccm.201309-1634ST. Erratum in: Am J Respir Crit Care Med. 2014 Jun 15;189(12):1570. PMID: 24127811.
88. Mador MJ, Bozkanat E. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Respir Res. 2001;2(4):216-24. doi: 10.1186/rr60. Epub 2001 May 2. PMID: 11686887; PMCID: PMC59579.
89. Waschki B, Kirsten A, Holz O, Müller KC, Meyer T, Watz H, Magnussen H. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011 Aug;140(2):331-342. doi: 10.1378/chest.10-2521. Epub 2011 Jan 27. PMID: 21273294.
90. Spruit MA, Polkey MI, Celli B, Edwards LD, Watkins ML, Pinto-Plata V, Vestbo J, Calverley PM, Tal-Singer R, Agusti A, Coxson HO, Lomas DA, MacNee W, Rennard S, Silverman EK, Crim CC, Yates J, Wouters EF; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study investigators. Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. J Am Med Dir Assoc. 2012 Mar;13(3):291-7. doi: 10.1016/j.jamda.2011.06.009. Epub 2011 Jul 21. PMID: 21778120.
91. McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015 Feb 23;2015(2):CD003793. doi: 10.1002/14651858.CD003793.pub3. PMID: 25705944; PMCID: PMC10008021.
92. Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol. 2011 Aug 5;11(9):607-15. doi: 10.1038/nri3041. PMID: 21818123.
93. Uzeloto JS, de Toledo-Arruda AC, Silva BSA, Braz AMM, de Lima FF, Grigoletto I, Ramos D, Golim MA, Ramos EMC. Effect of physical training on cytokine expression in CD4+ T lymphocytes in subjects with stable COPD. Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221091179. doi: 10.1177/17534666221091179. Erratum in: Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221115274. PMID: 35695009; PMCID: PMC9189509.
94. Wang X, Wang Z, Tang D. Aerobic Exercise Alleviates Inflammation, Oxidative Stress, and Apoptosis in Mice with Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2021 May 17;16:1369-1379. doi: 10.2147/COPD.S309041. Erratum in: Int J Chron Obstruct Pulmon Dis. 2021 Nov 24;16:3201-3202. PMID: 34040365; PMCID: PMC8139730.
95. Nikniaz L, Ghojazadeh M, Nateghian H, Nikniaz Z, Farhangi MA, Pourmanaf H. The interaction effect of aerobic exercise and vitamin D supplementation on inflammatory factors, anti-inflammatory proteins, and lung function in male smokers: a randomized controlled trial. BMC Sports Sci Med Rehabil. 2021 Aug 30;13(1):102. doi: 10.1186/s13102-021-00333-w. PMID: 34461991; PMCID: PMC8406718.
96. Ramos EM, de Toledo-Arruda AC, Fosco LC, Bonfim R, Bertolini GN, Guarnier FA, Cecchini R, Pastre CM, Langer D, Gosselink R, Ramos D. The effects of elastic tubing-based resistance training compared with conventional resistance training in patients with moderate chronic obstructive pulmonary disease: a randomized clinical trial. Clin Rehabil. 2014 Nov;28(11):1096-106. doi: 10.1177/0269215514527842. Epub 2014 Mar 19. PMID: 24647863.
97. Ryrsø CK, Thaning P, Siebenmann C, Lundby C, Lange P, Pedersen BK, Hellsten Y, Iepsen UW. Effect of endurance versus resistance training on local muscle and systemic inflammation and oxidative stress in COPD. Scand J Med Sci Sports. 2018 Nov;28(11):2339-2348. doi: 10.1111/sms.13227. Epub 2018 Jun 19. PMID: 29802649.
98. Silva BSA, Lira FS, Rossi FE, Ramos D, Uzeloto JS, Freire APCF, de Lima FF, Gobbo LA, Ramos EMC. Inflammatory and Metabolic Responses to Different Resistance Training on Chronic Obstructive Pulmonary Disease: A Randomized Control Trial. Front Physiol. 2018 Mar 23;9:262. doi: 10.3389/fphys.2018.00262. PMID: 29628896; PMCID: PMC5877487.
99. Eda N, Shimizu K, Suzuki S, Tanabe Y, Lee E, Akama T. Effects of yoga exercise on salivary beta-defensin 2. Eur J Appl Physiol. 2013 Oct;113(10):2621-7. doi: 10.1007/s00421-013-2703-y. Epub 2013 Aug 8. PMID: 23925803.
100. Oh B, Bae K, Lamoury G, Eade T, Boyle F, Corless B, Clarke S, Yeung A, Rosenthal D, Schapira L, Back M. The Effects of Tai Chi and Qigong on Immune Responses: A Systematic Review and Meta-Analysis. Medicines (Basel). 2020 Jun 30;7(7):39. doi: 10.3390/medicines7070039. PMID: 32629903; PMCID: PMC7400467.
- Abstract Viewed: 95 times